Positive allosteric interaction of structurally diverse T-type calcium channel antagonists

Cell Biochemistry and Biophysics

Volumn 55, Issue 2, 2009, Pages 81-93

  Uebele, Victor N ^a   Nuss, Cindy E ^a   Fox, Steven V ^a   Garson, Susan L ^a   Cristescu, Razvan ^a   Doran, Scott M ^a   Kraus, Richard L ^a   Santarelli, Vincent P ^a   Li, Yuxing ^a   Barrow, James C ^a   Yang, Zhi Qiang ^a   Schlegel, Kelly Ann S ^a   Rittle, Kenneth E ^a   Reger, Thomas S ^a   Bednar, Rodney A ^a   Lemaire, Wei ^a   Mullen, Faith A ^a   Ballard, Jeanine E ^a   Tang, Cuyue ^a   Dai, Ge ^a   McManus, Owen B ^a   Koblan, Kenneth S ^a   Renger, John J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Absence epilepsy; CACNA1I; CaV3; Radioligand; Seizure; Synergy; T type calcium channel

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE;

ALLOSTERISM; ANIMAL; ARTICLE; BINDING SITE; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; WISTAR RAT;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CELLS, CULTURED; HUMANS; MALE; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 71449104987     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-009-9057-4     Document Type: Article

References (44)

1. Broicher, T., Kanyshkova, T., Meuth, P., Pape, H. C., & Budde, T. (2008). Correlation of T-channel coding gene expression, IT, and the low threshold Ca2+ spike in the thalamus of a rat model of absence epilepsy. Molecular and Cellular Neurosciences, 39, 384-399.
2. Kim, D., Song, I., Keum, S., Lee, T., Jeong, M. J., Kim, S. S., et al. (2001). Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha(1G) T-type Ca(2+) channels. Neuron, 31, 35-45.
3. McCormick, D. A. (2002). Cortical and subcortical generators of normal and abnormal rhythmicity. International Review of Neurobiology, 49, 99-114.
4. McCormick, D. A., & Contreras, D. (2001). On the cellular and network bases of epileptic seizures. Annual Review of Physiology, 63, 815-846.
5. Lotshaw, D. P. (2001). Role of membrane depolarization and T-type Ca2+ channels in angiotensin II and K+ stimulated aldosterone secretion. Molecular and Cellular Endocrinology, 175, 157-171.
6. Chen, X. L., Bayliss, D. A., Fern, R. J., & Barrett, P. Q. (1999). A role for T-type Ca2+ channels in the synergistic control of aldosterone production by ANG II and K+. American Journal of Physiology, 276, F674-F683.
7. Taylor, J. T., Zeng, X. B., Pottle, J. E., Lee, K., Wang, A. R., Yi, S. G., et al. (2008). Calcium signaling and T-type calcium channels in cancer cell cycling. World Journal of Gastroenterology, 14, 4984-4991.
8. Taylor, J. T., Huang, L., Pottle, J. E., Liu, K., Yang, Y., Zeng, X., et al. (2008). Selective blockade of T-type Ca2+ channels suppresses human breast cancer cell proliferation. Cancer Letters, 267, 116-124.
9. Gray, L. S., & Macdonald, T. L. (2006). The pharmacology and regulation of T type calcium channels: New opportunities for unique therapeutics for cancer. Cell Calcium, 40, 115-120.
10. Panner, A., & Wurster, R. D. (2006). T-type calcium channels and tumor proliferation. Cell Calcium, 40, 253-259.
11. Zamponi, G. W., Lewis, R. J., Todorovic, S., M., Arneric, S., P., & Snutch, T. P. (2008). Role of voltage calcium channels in ascending pain pathway. Brain Research Reviews, 60, 84-89.
12. Todorovic, S. M., & Jevtovic-Todorovic, V. (2006). The role of T-type calcium channels in peripheral and central pain processing. CNS & Neurological Disorders Drug Targets, 5, 639-653.
13. Barton, M. E., Eberle, E. L., & Shannon, H. E. (2005). The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. European Journal of Pharmacology, 521, 79-85.
14. Bourinet, E., Alloui, A., Monteil, A., Barrere, C., Couette, B., Poirot, O., et al. (2005). Silencing of the Cav3. 2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO Journal, 24, 315-324.
15. Uebele, V. N., Gotter, A. L., Nuss, C. E., Kraus, R. L., Doran, S. M., Garson, S. L., et al. (2009). Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. Journal of Clinical Investigation, 119, 1659-1667.
16. Llinas, R. R., Ribary, U., Jeanmonod, D., Kronberg, E., & Mitra, P. P. (1999). Thalamocortical dysrhythmia: A neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proceedings of the National Academy of Sciences of the United States of America, 96, 15222-15227.
17. Shipe, W. D., Barrow, J. C., Yang, Z. Q., Lindsley, C. W., Yang, F. V., Schlegel, K. A., et al. (2008). Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. Journal of Medicinal Chemistry, 51, 3692-3695.
18. Yang, Z. Q., Barrow, J. C., Shipe, W. D., Schlegel, K. A., Shu, Y., Yang, F. V., et al. (2008). Discovery of 1, 4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. Journal of Medicinal Chemistry, 51, 6471-6477.
19. Uebele, V. N., Nuss, C. E., Santarelli, V. P., Garson, S. L., Kraus, R. L., Barrow, J. C., et al. (2009). T-type calcium channels regulate cortical plasticity in-vivo. NeuroReport, 20, 257-262.
20. Lory, P., & Chemin, J. (2007). Towards the discovery of novel T-type calcium channel blockers. Expert Opinion on Therapeutic Targets, 11, 717-722.
21. McGivern, J. G. (2006). Pharmacology and drug discovery for T-type calcium channels. CNS & Neurological Disorders Drug Targets, 5, 587-603.
22. Lacinova, L. (2004). Pharmacology of recombinant low-voltage activated calcium channels. Current Drug Targets. CNS and Neurological Disorders, 3, 105-111.
23. Ertel, E. A., Campbell, K. P., Harpold, M. M., Hofmann, F., Mori, Y., Perez-Reyes, E., et al. (2000). Nomenclature of voltage-gated calcium channels. Neuron, 25, 533-535.
24. Mitterdorfer, J., Grabner, M., Kraus, R. L., Hering, S., Prinz, H., Glossmann, H., et al. (1998). Molecular basis of drug interaction with L-type Ca2+ channels. Journal of Bioenergetics and Biomembranes, 30, 319-334.
25. Hockerman, G. H., Peterson, B. Z., Johnson, B. D., & Catterall, W. A. (1997). Molecular determinants of drug binding and action on L-type calcium channels. Annual Review of Pharmacology and Toxicology, 37, 361-396.
26. Glossmann, H., Ferry, D. R., Goll, A., & Rombusch, M. (1984). Molecular pharmacology of the calcium channel: Evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1, 4-dihydropyridine calcium channel label, [125I]iodipine. Journal of Cardiovascular Pharmacology, 6(Suppl 4), S608-S621.
27. Triggle, D. J. (2007). Calcium channel antagonists: Clinical uses-past, present and future. Biochemical Pharmacology, 74, 1-9.
28. Barrett, T. D., Triggle, D. J., Walker, M. J., & Maurice, D. H. (2005). Mechanism of tissue-selective drug action in the cardiovascular system. Molecular Interventions, 5, 84-93.
29. Triggle, D. J. (1992). Calcium-channel antagonists: Mechanisms of action, vascular selectivities, and clinical relevance. Cleveland Clinic Journal of Medicine, 59, 617-627.
30. Triggle, D. J. (1991). Sites, mechanisms of action, and differentiation of calcium channel antagonists. American Journal of Hypertension, 4, 422S-429S.
31. May, L. T., Leach, K., Sexton, P. M., & Christopoulos, A. (2007). Allosteric modulation of G protein-coupled receptors. Annual Review of Pharmacology and Toxicology, 47, 1-51.
32. Ijjaali, I., Barrere, C., Nargeot, J., Petitet, F., & Bourinet, E. (2007). Ligand-based virtual screening to identify new T-type calcium channel blockers. Channels, 1, 300-304.
33. Doddareddy, M. R., Choo, H., Cho, Y. S., Rhim, H., Koh, H. Y., Lee, J. H., et al. (2007). 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorganic & Medicinal Chemistry, 15, 1091-1105.
34. Doddareddy, M. R., Jung, H. K., Lee, J. Y., Lee, Y. S., Cho, Y. S., Koh, H. Y., et al. (2004). First pharmacophoric hypothesis for T-type calcium channel blockers. Bioorganic & Medicinal Chemistry, 12, 1605-1611.
35. Horn, R., & Marty, A. (1988). Muscarinic activation of ionic currents measured by a new whole-cell recording method. Journal of General Physiology, 92, 145-159.
36. Xia, M., Imredy, J. P., Koblan, K. S., Bennett, P., & Connolly, T. M. (2004). State-dependent inhibition of L-type calcium channels: Cell-based assay in high-throughput format. Analytical Biochemistry, 327, 74-81.
37. Dai, G., Haedo, R. J., Warren, V. A., Ratliff, K. S., Bugianesi, R. M., Rush, A., et al. (2008). A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Development Technologies, 6, 195-212.
38. Barrow, J. C., Bieber, K. A. S., Cube, R. V., Mattern, M. C., Reger, T. S., Shu, Y. et al. (2007). Pyridyl amide T-type calcium channel antagonists. U. S. Patent WO 2007120729.
39. Barrow, J. C., Cube, R. V., Ngo, P. L., Rittle, K. E., Yang, Z. Q., & Young, S. D. (2006). Preparation of quinazolinones as T-type calcium channel antagonists. U. S. Patent WO 2006098969.
40. Ernst, W. L., Zhang, Y., Yoo, J. W., Ernst, S. J., & Noebels, J. L. (2009). Genetic enhancement of thalamocortical network activity by elevating alpha1g-mediated low-voltage-activated calcium current induces pure absence epilepsy. Journal of Neuroscience, 29, 1615-1625.
41. Contreras, D. (2006). The role of T-channels in the generation of thalamocortical rhythms. CNS & Neurological Disorders Drug Targets, 5, 571-585.
42. Xie, X., van Deusen, A. L., Vitko, I., Babu, D. A., Davies, L. A., Huynh, N., et al. (2007). Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches. Assay Drug Development Technologies, 5, 191-203.
43. McCormick, D. A., & Bal, T. (1997). Sleep and arousal: Thalamocortical mechanisms. Annual Review of Neuroscience, 20, 185-215.
44. Avanzini, G., Panzica, F., & de Curtis, M. (2000). The role of the thalamus in vigilance and epileptogenic mechanisms. Clinical Neurophysiology, 111(Suppl 2), S19-S26.